Asunaprevir

Asunaprevir (formerly BMS-650032, brand name in Japan and Russia^[1] Sunvepra) is an experimental drug candidate for the treatment of hepatitis C. It was undergoing development by Bristol-Myers Squibb and has completed Phase III clinical trials in 2013.^[2]

Asunaprevir

Clinical data
Other names	BMS-650032
ATC code	J05AP06 (WHO)
Identifiers
IUPAC name tert-butyl N-[(2S)-1-[(2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
CAS Number	630420-16-5
PubChem CID	16076883
IUPHAR/BPS	10882
DrugBank	DB11586
ChemSpider	17235944
UNII	S9X0KRJ00S
KEGG	D10093
ChEBI	CHEBI:134723
ChEMBL	ChEMBL2105735
CompTox Dashboard (EPA)	DTXSID201026065
ECHA InfoCard	100.206.482
Chemical and physical data
Formula	C35H46ClN5O9S
Molar mass	748.29 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C
InChI InChI=InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1 Key:XRWSZZJLZRKHHD-WVWIJVSJSA-N

Asunaprevir is an inhibitor of the hepatitis C virus enzyme serine protease NS3.^[3] Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.^[4][5][6]